Jonas Brånalt
AstraZeneca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jonas Brånalt.
Tetrahedron | 1997
Daniel Nöteberg; Jonas Brånalt; Ingemar Kvarnström; Björn Classon; Bertil Samuelsson; Ulrika Nillroth; U. Helena Danielson; Anders Karlén; Anders Hallberg
The synthesis of the four diastereomeric 2-aminocyclopentanecarboxylic acids, their use as replacements for proline in potential HIV protease inhibitors containing a hydroxyethylamine dipeptide isostere and the evaluation of the biological activity of these is described.
Bioorganic & Medicinal Chemistry | 2002
Anders Dahlgren; Jonas Brånalt; Ingemar Kvarnström; Ingemar Nilsson; Djordje Musil; Bertil Samuelsson
With the objective to prepare novel non-peptidic thrombin inhibitors, bioisosteres of the inhibitory tripeptide D-Phe-Pro-Arg chain have been examined. Thus, the P1 Arg was replaced with p-amidinobenzylamine, an elongated homologue of the same and with 2,5-dichloro benzylamine. The P2-P3, D-Phe-Pro, was replaced with a novel tartaric acid template coupled to a series of readily available, mainly lipophilic, amines. Some of these compounds exhibit promising thrombin inhibition activity in vitro, IC(50 ) approximately 5.9 microM.
Organic Letters | 2017
Alexander Wetzel; Joakim Bergman; Peter Brandt; Mats Larhed; Jonas Brånalt
Pd(0)-catalyzed Mizoroki-Heck alkenylations and arylations of protected aminocyclopentenes, prepared in a few steps from Vince lactam, afforded functionalized cyclopentenes in high yields and stereoselectivities. DFT calculations were performed to rationalize the high diastereoselectivities. Functionalized cyclopentene products were transformed into valuable chiral building blocks, such as cyclic γ-amino acids and carbocyclic nucleoside precursors.
Journal of Organic Chemistry | 2016
Christoffer Bengtsson; Alexander Wetzel; Joakim Bergman; Jonas Brånalt
The unexpected retroaldol-aldol reaction during O-alkylation of a β-hydroxy lactam was found to be highly dependent on the temperature and shows a remarkable solvent effect. In DMF, O-alkylation is faster than retroaldol-aldol rearrangement giving exclusively products with retention of configuration. In THF, O-alkylation is slower than rearrangement, giving selectively products with inversion of stereochemistry. In DMSO, a retroaldol reaction followed by fast intramolecular proton transfer occurs to give the ring-opened aldehyde.
Organic Letters | 2017
Tamal Roy; Peter Brandt; Alexander Wetzel; Joakim Bergman; Jonas Brånalt; Jonas Sävmarker; Mats Larhed
We report a highly diastereoselective synthesis of cyclopentene-spirooxindole derivatives via an intramolecular Heck-Mizoroki reaction using aryl bromides as precursors. The reactions were performed under dry conditions or in a DMF-water system. This protocol can be useful to introduce several functionalities to the aromatic nucleus of the spirooxindoles. DFT calculations were performed to rationalize the high antiselectivity. A functionalized spiroproduct was transformed into a cyclic amino acid derivative.
Journal of Medicinal Chemistry | 2016
Vincent Andersson; Fredrik Bergström; Jonas Brånalt; Gunnar Grönberg; David Gustafsson; Staffan Karlsson; Magnus Polla; Joakim Bergman; Jan Kihlberg
The only oral direct thrombin inhibitors that have reached the market, ximelagatran and dabigatran etexilat, are double prodrugs with low bioavailability in humans. We have evaluated an alternative strategy: the preparation of a nonpeptidic, polar direct thrombin inhibitor as a single, macrocyclic esterase-cleavable (acyloxy)alkoxy prodrug. Two homologous prodrugs were synthesized and displayed high solubilities and Caco-2 cell permeabilities, suggesting high absorption from the intestine. In addition, they were rapidly and completely converted to the active zwitterionic thrombin inhibitor in human hepatocytes. Unexpectedly, the most promising prodrug displayed only moderately higher oral bioavailability in rat than the polar direct thrombin inhibitor, most likely due to rapid metabolism in the intestine or the intestinal wall. To the best of our knowledge, this is the first in vivo ADME study of macrocyclic (acyloxy)alkoxy prodrugs, and it remains to be established if the modest increase in bioavailability is a general feature of this category of prodrugs or not.
Journal of Medicinal Chemistry | 2000
Daniel Nöteberg; Jonas Brånalt; Ingemar Kvarnström; Marcel Linschoten; Djordje Musil; Jan-Erik Nyström; Guido Zuccarello; Bertil Samuelsson
Tetrahedron Letters | 1997
Jonas Brånalt; Ingemar Kvarnström; Björn Classon; Bertil Samuelsson; Ulrika Nillroth; U. Helena Danielson; Anders Karlén; Anders Hallberg
Molecules Online | 1998
Bertil Samuelsson; Jonas Brånalt; Gunilla Niklasson; Ingemar Kvarnström; Björn Classon
Organic Process Research & Development | 2014
Staffan Karlsson; Jonas Brånalt; Maria Ölwegård Halvarsson; Joakim Bergman